Amgen Inc. Stock price

Equities

AMGN

US0311621009

Pharmaceuticals

Real-time Estimate Cboe BZX 03:32:58 2024-03-28 pm EDT 5-day change 1st Jan Change
284.9 USD -0.49% Intraday chart for Amgen Inc. +2.82% -1.13%
Sales 2024 * 33.01B Sales 2025 * 34.06B Capitalization 153B
Net income 2024 * 6.13B Net income 2025 * 7.57B EV / Sales 2024 * 6.06 x
Net Debt 2024 * 46.57B Net Debt 2025 * 40.77B EV / Sales 2025 * 5.7 x
P/E ratio 2024 *
24.8 x
P/E ratio 2025 *
19.2 x
Employees 26,700
Yield 2024 *
3.23%
Yield 2025 *
3.5%
Free-Float 99.75%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.17%
1 week+3.38%
Current month+4.56%
1 month+3.19%
3 months-0.74%
6 months+5.72%
Current year-0.59%
More quotes
1 week
275.10
Extreme 275.1
288.57
1 month
268.17
Extreme 268.17
288.57
Current year
268.17
Extreme 268.17
329.72
1 year
211.71
Extreme 211.71
329.72
3 years
198.64
Extreme 198.64
329.72
5 years
166.30
Extreme 166.3
329.72
10 years
108.20
Extreme 108.2
329.72
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 06-05-31
Director of Finance/CFO 65 19-10-22
Chief Tech/Sci/R&D Officer 53 -
Members of the board TitleAgeSince
Director/Board Member 67 17-02-02
Director/Board Member 68 16-10-13
Director/Board Member 75 14-10-16
More insiders
Date Price Change Volume
24-03-28 284.7 -0.57% 958 885
24-03-27 286.3 +1.61% 2,256,315
24-03-26 281.8 +0.34% 3,343,181
24-03-25 280.8 +1.68% 2,954,416
24-03-22 276.2 -0.28% 2,303,249

Delayed Quote Nasdaq, March 28, 2024 at 11:38 am EDT

More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
286.3 USD
Average target price
304.8 USD
Spread / Average Target
+6.45%
Consensus
  1. Stock
  2. Equities
  3. Stock Amgen Inc. - Nasdaq